On this page
Adcetris
brentuximab vedotin
351(a) Standalone BLA
Overview
Source: Purple BookProprietary name
Adcetris
Proper name
brentuximab vedotin
Licence type
351(a)
BLA number
125388
Applicant
Seagen Inc.
Center
CDER
Presentations
1
First licensure
—
Presentations
Source: Purple Book| Strength | Dosage form | Route | Presentation | Status | Licensed |
|---|---|---|---|---|---|
| 50MG | For Injection | Intravenous | Single-Dose Vial | Rx | August 19, 2011 |
Exclusivity
Source: Purple Book| Kind | Expires |
|---|---|
| Orphan exclusivity | November 10, 2029 |
Sources for this page
| Purple Book | FDA | Licence type, presentations, reference product, exclusivity |